ObjectiveTo report a case of port-site metastasis (PSM) after laparoscopic treatment for borderline ovarian tumor (BOT), and to discuss the safety and efficacy of laparoscopic treatment for BOT as well as whether chemotherapy is beneficial for BOT patients. MethodsWe retrospectively studied a case of PSM after laparoscopic treatment of a micropapillary borderline ovarian tumor in August 2013, and reviewed the related literatures in PubMed and Cochrane databases from 1929 to 2014 using "port-site metastasis", "borderline ovarian tumor" , "laparoscopy" , "chemotherapy" as the subject words. ResultsAfter conservative operation and chemotherapy of "carboplatin and taxol" for 8 times, the subcutaneous nodes didn't shrink and the level of CA125 didn't reduce. Though some studies supported that laparoscopy was safe and effective for early-stage ovarian cancer and BOT, there was no high-quality evidence to help quantify the risks and benefits of laparoscopy for the management of early-stage ovarian cancer as routine clinical practice. While early researches suggested adjunctive chemotherapy benefited BOT patients, the subsequent studies indicated opposite results. Therefore, it was still controversial and a lack of high quality evidence existed. However, chemotherapy was recommended for those with high risks. ConclusionLaparotomy is still the standard treatment for ovarian tumor. For patients with low risks and requiring minimally invasive therapy, laparoscopy is an alternative choice, but it should be staged completely. For those with high risks or laparoscopy is difficult to perform, it should be converted to laparotomy as soon as possible. All these procedures should be completed by experienced and skillful gynecologic oncologists. For those with high risks, it is recommended that they should receive chemotherapy and be followed up for a long time.